A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Eczema

In brief

This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to \<12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to receive either abrocitinib test medicine or placebo (pretend medicine that looks just like the test medicine) for 16 weeks. The study will last for about 24 weeks in total.

Key facts

Study ID

NCT06807268

Run by

Pfizer

People needed

150

Starts

2025-07-24

Expected to finish

2027-05-02

Last updated by the study team

2026-07-22

Who can join

Age: 6 and older, up to 11. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Participants are excluded from the study if any of the following criteria apply:
• Medical Conditions:
• Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.
• Have any of the following medical conditions:
• Infections:
• Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (Baseline) or have superficial skin infections within 1 week of Day 1.
• History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.
• Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
• Infection with HIV, hepatitis B, and/or hepatitis C
• Evidence of active TB or inadequately treated latent TB.
• Skin Conditions:
• Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.
• Other Conditions:
• Documented history of skeletal dysplasia.
• Documented history of retinal detachment.
• History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
• Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
• Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
• Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.
• Prior/Concomitant Therapy:
• Prior treatment with a systemic JAK inhibitor for AD. Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.
• Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes, strong inducers of CYP2C9 enzymes, P-gp substrates with narrow therapeutic index and sensitive CYP2C19 substrates is not allowed in the study.
• Prior/Concurrent Clinical Study Experience:
• Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.

Where it is running

• Hospital Universitario Miguel Servet — Zaragoza, Spain (enrolling)
• Arkansas Research Trials — North Little Rock, Arkansas, United States (enrolling)
• Investigational Drug Service - Rady Childrens Hospital-San Diego — San Diego, California, United States (enrolling)
• University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm — San Diego, California, United States (enrolling)
• Solutions Through Advanced Research — Jacksonville, Florida, United States (enrolling)
• Ada West Research — Meridian, Idaho, United States (enrolling)
• Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana, United States (enrolling)
• Saint Louis University - Department of Dermatology — St Louis, Missouri, United States (enrolling)
• Medical University of South Carolina — Charleston, South Carolina, United States (enrolling)
• Tribe Clinical Research, LLC — Greenville, South Carolina, United States (enrolling)
• Texas Dermatology and Laser Specialists — San Antonio, Texas, United States (enrolling)
• Beijing Children's hospital, Capital Medical University — Beijing, Beijing Municipality, China (enrolling)
• Shenzhen Children's Hospital — Shenzhen, Guangdong, China (enrolling)
• Hunan Children's Hospital — Changsha, Hunan, China (enrolling)
• Dermatology Hospital of Jiangxi Province — Nanchang, Jiangxi, China (enrolling)
• Shanghai Children's Hospital — Shanghai, Shanghai Municipality, China (enrolling)
• Hangzhou Third People's Hospital — Hangzhou, Zhejiang, China (enrolling)
• Shanghai Children's Hospital — Shanghai, China (enrolling)
• Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine — Shanghai, China (enrolling)
• Universitätsklinikum Münster — Münster, North Rhine-Westphalia, Germany (enrolling)
• Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden — Dresden, Saxony, Germany (enrolling)
• Pécsi Tudományegyetem Klinikai Központ — Pécs, Baranya, Hungary (enrolling)
• Trial Pharma Kft. — Békéscsaba, Bekes County, Hungary (enrolling)
• Clinexpert Kft. — Budapest, Pest County, Hungary (enrolling)
• University of Pecs — Pécs, Hungary (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.